Related references
Note: Only part of the references are listed.Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes
Claudio Laudani et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2022)
Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
You-Jeong Ki et al.
KOREAN CIRCULATION JOURNAL (2022)
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome The STOPDAPT-2 ACS Randomized Clinical Trial
Hirotoshi Watanabe et al.
JAMA CARDIOLOGY (2022)
Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis
Toshiki Kuno et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2022)
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Jean-Philippe Collet et al.
EUROPEAN HEART JOURNAL (2021)
Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis
Young-Hoon Jeong et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)
Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial
Young-Hoon Jeong et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial
Chan Joon Kim et al.
LANCET (2021)
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Mattia Galli et al.
LANCET (2021)
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
Marco Valgimigli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial
Pascal Vranckx et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease
Hyun Kuk Kim et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial
Marieke Gimbel et al.
LANCET (2020)
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome The TICO Randomized Clinical Trial
Byeong-Keuk Kim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial
Hyo-Soo Kim et al.
LANCET (2020)
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention The SMART-CHOICE Randomized Clinical Trial
Joo-Yong Hahn et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI The STOPDAPT-2 Randomized Clinical Trial
Hirotoshi Watanabe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management A Randomized Clinical Trial
Duk-Woo Park et al.
CIRCULATION (2019)
Ticagrelor with or without Aspirin in High-Risk Patients after PCI
R. Mehran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Daniel M. F. Claassens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
S. Schuepke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)
Giuseppe De Luca et al.
EUROINTERVENTION (2019)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
Borja Ibanez et al.
EUROPEAN HEART JOURNAL (2018)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2018)
Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization
Stefano Savonitto et al.
CIRCULATION (2018)
1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor
Zuzana Motovska et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
Joo-Yong Hahn et al.
LANCET (2018)
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
Pascal Vranckx et al.
LANCET (2018)
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study
Thomas Cuisset et al.
EUROPEAN HEART JOURNAL (2017)
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
Dirk Sibbing et al.
LANCET (2017)
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents)
Jennifer Yu et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2017)
Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent Randomized Substudy of the I-LOVE-IT 2 Trial
Yaling Han et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2016)
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Xiuying Tang et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2016)
Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome
Huidong Wang et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis
Raphaela Lohaus et al.
SCIENTIFIC REPORTS (2016)
Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndrome - Randomized, Double-Blind, Phase III PHILO Study -
Shinya Goto et al.
CIRCULATION JOURNAL (2015)
Duration of Dual Antiplatelet Therapy After Coronary Stenting A Review of the Evidence
Gilles Montalescot et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization: Insights Into the Safety of Long-Term Dual Antiplatelet Therapy With Reduced-Dose Prasugrel Versus Standard-Dose Clopidogrel
Matthew T. Roe et al.
CIRCULATION (2013)
Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents The OPTIMIZE Randomized Trial
Fausto Feres et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study
Gregg W. Stone et al.
LANCET (2013)
Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study
Hyeon-Cheol Gwon et al.
CIRCULATION (2012)
Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Gjin Ndrepepa et al.
CIRCULATION (2012)
A New Strategy for Discontinuation of Dual Antiplatelet Therapy The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
Byeong-Keuk Kim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention
Elliott M. Antman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Share Paper
